Valproate: survey on awareness of teratogenicity risk and impact of risk minimisation measures in women of childbearing age.

Study identification

• EU PAS number:
  EUPAS1000000735
• Study ID:
  1000000735
• Official title and acronym:
  Valproate: survey on awareness of teratogenicity risk and impact of risk minimisation measures in women of childbearing age.
• DARWIN EU® study:
  No
• Study countries:
  Belgium
• Study description:
  This is a cross-sectional survey to assess the effectiveness of RMMs in preventing valproate exposure during pregnancy in Belgium.
• Study status:
  Finalised

Research institutions and networks

Institutions

Federal Agency for Medicines and Health Products (FAMHP)

Study timelines

Date when funding contract was signed

Planned:01/06/2024

Actual:01/06/2024

Study start date

Planned:01/10/2025

Actual:13/10/2025

Data analysis start date

Planned:01/03/2026

Actual:02/03/2026

Date of final study report

Planned:02/11/2026

Actual:13/07/2026

Sources of funding

National competent authority (NCAs)

More details on funding

No information provided.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable